|
Abiomed, Inc., a cardiovascular device company, is a leading developer, manufacturer, and marketer of medical products designed to establish “recovery” as the standard of care for acute patients. Currently marketed products include AbioCor (totally artificial heart), as well as 2 products designed for heart recovery following acute events: the AB5000 and BVS 5000.
The Achilles heal of the approved portfolio is the Impella product line, the world’s smallest, minimally invasive, high performance micro blood pump with integrated motors and sensors. Impella’s Recover System pumps are designed to provide ventricle support for patients requiring hemodynamic stabilization, or suffering from reduced cardiac output, and can potentially aid in recovering the hearts of patients suffering from acute myocardial infarction and those undergoing high risk percutaneous coronary interventions- giving the company a major presence in the cath lab.
Accumetrics, Inc., a point-of-care diagnostic company, develops, manufactures, and markets the VerifyNow™ System, a comprehensive system for the assessment of platelet function. Modulation of platelet function plays a critical role in effectively treating cardiovascular, cerebrovascular, and peripheral vascular disease. Accumetrics markets VerifyNow™ tests for aspirin, Plavix® and GP IIb/IIIa inhibitors.
ATS Medical, Inc., engages in the development, manufacture and marketing of medical devices for the treatment of structural heart diseases. It offers prosthetic heart valves, such as ATS Open Pivot Heart Valve, as well as ATS 3F Aortic Bioprosthesis, a biological replacement aortic heart valve and heart valve repair products. The company also markets and sells surgical cryoablation products for the treatment of cardiac arrhythmias, and it is developing minimally invasive and off-pump aortic valve concepts.
Bioform Medical, Inc., is a medical device company introducing a family of proprietary, injectable implant products used in minimally invasive soft tissue augmentation procedures. The lead product, Radiesse™, will be used for aesthetic/cosmetic indications.
Clear Vascular, Inc., was founded by Essex Woodlands Health Ventures in 2005 to develop innovative cardiovascular products.
Entellus Medical develops innovative ENT (ear, nose and throat) device technology and treatment solutions that benefit patients, physicians, and payers. Entellus recently introduced FinESS™ Sinus Treatment, a simple and direct approach to effectively treat patients with Chronic Rhinosinusitis (CRS). FinESS™ Sinus Treatment is less invasive, reduces pain and bleeding, shortens recovery time, and eliminates the need for general anesthesia.
Echo Therapeutics, Inc., is focused on transdermal continuous glucose monitoring (tCGM) systems for people with diabetes and advanced topical reformulations of FDA-approved specialty pharmaceuticals.
Echo's Symphony™ tCGM System is a next generation, non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system in development for home use and hospital critical care markets. Symphony incorporates Echo's patented feedback mechanism for optimal skin permeation control and its non-invasive, continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing in home use and hospital critical care settings with technology designed to improve patient compliance and achieve better overall glucose control.
InSound Medical, Inc., is an early stage company founded in 1998 to develop minimally invasive hearing products designed to overcome dissatisfaction among current hearing aid wearers, as well as barriers to use among hearing impaired non-users. The Company will utilize ear-nose-throat (ENT) physicians to market and install their devices. ENTs have heretofore been excluded from the $2 billion hearing aid market.
LipoSonix, Inc., is a medical device company focused on the development of proprietary technology for noninvasive cosmetic surgery applications. Current product development efforts are targeted at the aesthetic body contouring market.
Medlogics Device Corp. is an early stage medical device company developing a broad platform technology for innovative drug delivery. The initial focus is product development of polymer-free stent drug delivery.
E-Wilson, LLC, (formerly MicroMed Cardiovascular, Inc.), has developed the DeBakey ventricular assist device (VAD) pioneered by heart surgeon Dr. Michael E. DeBakey under a joint research and development collaboration with NASA. The DeBakey VAD serves as a bridge to heart transplant, to native heart recovery, and/or treatment for congestive heart failure.
MicroPort Medical (Shanghai) Co. Ltd. is an entrepreneurial, innovative company which provides leading technologies and products to physicians with life-saving solutions and treatments for patients. In close cooperation with recognized international physicians and scientists worldwide, the company has developed a range of interventional vascular products that meet the highest quality and clinical standards.
Nellix Endovascular, Inc., is a privately funded, medical device startup company which is actively developing novel solutions to vascular diseases that affect millions of patients world wide.
NeoVista, Inc. is developing an intraocular epiretinal radiation device intended for the treatment of the wet form of Age-Related Macular Degeneration (AMD).
Novacept designs, develops, manufactures and markets innovative therapeutic
devices to improve the quality of women's healthcare in a cost-effective
manner. Novacept was sold to
Cytyc Corporation in March 2004.
Oraya Therapeutics, Inc., is a privately held company
developing medical devices.
Orthovita is a unique spine/orthopedic surgical biomaterials company offering advanced bone regeneration and soft tissue healing technologies. Their experience lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Orthovita currently has four key commercial product platforms: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems.
Proteus Biomedical, Inc., was founded in 2001 to apply its state-of-the-art semiconductor technology to the treatment of cardiovascular disease. The company's clinical focus is on the management of congestive heart failure (CHF), a debilitating condition resulting from progressive weakening of the heart's pumping capability.
QSpex Technologies, Inc., has developed the unique and patented Lens Transformation Technology. The system allows eye care specialists to produce high quality, premium ophthalmic lenses, including anti-reflective, photochromic, and polarized, at the point of sale in under 30 minutes. The Lens Transformation Technology system offers many business advantages as it takes up little space, is quick and easy to operate, requires minimal capital expenditure and pays for itself with significant savings over traditional, lab-produced lenses.
ROX Medical, Inc., represents a mid-late stage medical device opportunity in the fast growing, underserved market of late end state COPD (chronic obstructive pulmonary disease) patients.
Solta Medical, Inc. (formerly Thermage, Inc.), designs, develops, manufactures and markets non-invasive skin tightening devices for cosmetic indications The technology has multiple potential applications, including treatments for facial skin tightening, acne and acne scarring, stretch marks, breast lifting and fat dissipation. Several types of disposable treatment tips are designed for various applications and anatomic sites. Solta Medical has secured regulatory clearance for marketing the system.
Sound ID, Inc.’s proprietary sound source signal enhancement technology, deployable in a wide variety of products in the communication and entertainment markets, provides personalization of sound to an individual’s unique hearing profile, and dynamic optimization of sound in response to noise in the listener’s environment.
United Orthopedic Group, Inc., (formerly dba Bledsoe Brace Systems) is a leader in the orthopedic bracing market. Founded in 1982, it was the first company to develop a post-operative knee brace, and has continued to build on its 25-year reputation of quality clinical products and design leadership. United Orthopedic Group’s products are used both domestically and internationally by orthopedic surgeons, podiatrists, orthotists, and physical therapists to address musculoskeletal disorders of their patients by supporting and protecting injured or weakened joints.
|
